Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells

被引:60
|
作者
Yeung, F
Li, XY
Ellett, J
Trapman, J
Kao, CH
Chung, LWK [1 ]
机构
[1] Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA
[2] Univ Virginia, Dept Urol, Charlottesville, VA 22908 USA
[3] Erasmus Univ, Dept Pathol, NL-3000 DR Rotterdam, Netherlands
[4] Indiana Canc Pavil, Dept Urol, Indianapolis, IN 46202 USA
关键词
D O I
10.1074/jbc.M002755200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate-specific antigen (PSA) is expressed primarily by both normal prostate epithelium and the vast majority of prostate cancers. Increases in serum PSA during endocrine therapy are generally considered as evidence for prostate cancer recurrence or progression to androgen independence. The mechanisms by which PSA upregulation occurs in androgen-refractory prostate cancer cells are unknown. In this study, by using LNCaP and its lineage-derived androgen-independent PSA-producing subline, C4-2, we identified two cis-elements within the 5.8-bilobase pair PSA promoter that are essential for the androgen-independent activity of PSA promoter in prostate cancer cells. First, a previously reported 440-bp androgen-responsive Element enhancer core (AREc) was found to be important for the high basal PSA promoter activity in C4-2 cells. Both mutation analysis and supershift experiments demonstrated that androgen receptor (AR) binds to the AREs within the AREc and activate the basal PSA promoter activity in C4-2 cells under androgen-deprived conditions. Second, a 150-bp pN/H region was demonstrated to be a strong AR-independent positive-regulatory element of the PSA promoter in both LNCaP and C4-2 cells. Through DNase I footprinting and linker scan mutagenesis, a 17-bp RI site was identified as the key cis-element within the pN/H region. Data from electrophoretic mobility shift analysis and UV cross-linking experiments further indicated that a 45-kDa (p45) cell-specific transcription factor associates with RI in prostate cancer cells and may be responsible for driving the PSA promoter activity independent of androgen and AR. Furthermore, by juxtaposing AREc and pN/H, we produced a chimeric PSA promoter (supra-PSA) that exhibits 2-3-fold higher activity than the wild type PSA promoter in both LNCaP and C4-2 cells.
引用
收藏
页码:40846 / 40855
页数:10
相关论文
共 50 条
  • [31] Novel polymorphisms of prostate-specific antigen (PSA) gene associated with PSA mRNA expression in breast cancer
    Yang, QF
    Sakurai, T
    Shan, L
    Yu, ZG
    Yoshimura, G
    Suzuma, T
    Tamaki, T
    Umemura, T
    Nakamura, M
    Nakamura, Y
    Mori, I
    Kakudo, K
    JOURNAL OF HUMAN GENETICS, 2000, 45 (06) : 363 - 366
  • [32] Assessment of Prostate-Specific Antigen (PSA) Kinetics in Prediction of Prostate Cancer on Prostate Biopsy
    Shinmei, S.
    Inoue, S.
    Ohkuchi, T.
    Yasukawa, A.
    UROLOGY, 2012, 80 (03) : S282 - S282
  • [33] Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
    Liu, Xin
    Tang, Jie
    Fei, Xiang
    Li, Qiu-Yang
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2015, 44 (11) : 1466 - 1472
  • [34] Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality
    D'Amico, Anthony V.
    McLeod, David G.
    Carroll, Peter R.
    Cullen, Jennifer
    Chen, Ming-Hui
    CANCER, 2007, 109 (07) : 1290 - 1295
  • [35] A UNIVERSAL CALIBRATOR FOR PROSTATE-SPECIFIC ANTIGEN (PSA)
    PRESTIGIACOMO, AF
    CHEN, Z
    STAMEY, TA
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1995, 55 : 57 - 59
  • [36] Substrate specificity of prostate-specific antigen (PSA)
    Coombs, GS
    Bergstrom, RC
    Pellequer, JL
    Baker, SI
    Navre, M
    Smith, MM
    Tainer, JA
    Madison, EL
    Corey, DR
    CHEMISTRY & BIOLOGY, 1998, 5 (09): : 475 - 488
  • [37] Antiangiogenic properties of prostate-specific antigen (PSA)
    Mattsson, Johanna M.
    Laakkonen, Pirjo
    Stenman, Ulf-Hakan
    Koistinen, Hannu
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2009, 69 (04): : 447 - 451
  • [38] Patient knowledge about prostate-specific antigen (PSA) and prostate cancer in Australia
    Pan, David
    McCahy, Philip
    BJU INTERNATIONAL, 2012, 109 : 52 - 56
  • [39] Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment
    Afshin Moradi
    Srilakshmi Srinivasan
    Judith Clements
    Jyotsna Batra
    Cancer and Metastasis Reviews, 2019, 38 : 333 - 346